Overview

Trametinib is an oral MEK1 and MEK2 inhibitor marketed as Mekinist, supplied in two milligram tablets. It acts downstream of BRAF in the RAS-RAF-MEK-ERK signaling cascade, making it relevant only for tumors driven by that pathway. Its use is tightly linked to biomarker testing: trametinib is indicated for BRAF V600-mutated cancers, most often in combination with the BRAF inhibitor dabrafenib. This article outlines the patient populations for whom pathway inhibition is appropriate and how selection is guided.

How It Works

MEK1 and MEK2 are kinases that transmit growth signals from mutated BRAF to the cell nucleus. By blocking these enzymes, trametinib interrupts a conversation that mutated cancer cells depend on for proliferation. Because MEK sits immediately after BRAF, combining a BRAF inhibitor with trametinib produces more durable pathway suppression than blocking a single node, a principle that shapes how the populations below are treated.

Indications

The clearest populations are those with a confirmed BRAF V600E or V600K alteration. Trametinib with dabrafenib is used in BRAF V600-mutated melanoma, in BRAF V600E-mutated non-small cell lung cancer, and in anaplastic thyroid carcinoma bearing the same mutation. Selection hinges on a valid molecular test rather than tumor site alone, which is why pathology-led biomarker screening precedes therapy.

Population Selection and Testing

Identifying the right population starts with reflexive BRAF testing on the tumor specimen. Patients without a V600 mutation derive no pathway-directed benefit and are directed to alternative strategies. Among mutation-positive individuals, factors such as prior therapy, performance status, and organ function inform whether combination treatment is suitable. For lung cancer specifically, the BRAF V600E subset is the relevant group. Procurement should mirror this precision: stock the combination where molecular diagnostics infrastructure can confirm eligibility, avoiding blanket distribution to settings without testing capacity.

FAQ

Q: Which patients should receive trametinib? A: Those with a confirmed BRAF V600E or V600K mutation, most commonly in melanoma, BRAF V600E non-small cell lung cancer, and anaplastic thyroid carcinoma, usually with dabrafenib.

Q: Is biomarker testing required before use? A: Yes. Trametinib targets the MEK node of the BRAF pathway, so a valid BRAF V600 test result is the precondition for appropriate use.

Q: Why is trametinib given with dabrafenib? A: Combining the BRAF and MEK inhibitors blocks the pathway at two points, which provides more complete and durable suppression than either agent alone.